This paper is in the following e-collection/theme issue:

Theme issue 2021: Outbreaks and Public Health Surveillance research in the Eastern Mediterranean Region (23) Outbreak and Pandemic Preparedness and Management (1743) Infectious Diseases (non-STD/STI) (1592) Innovative Methods in Public Health and Surveillance (336) Hygiene and Infection Prevention (325) JMIR Theme Issue: COVID-19 Special Issue (2461) Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1520)

Published on in Vol 7, No 5 (2021): May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/27609, first published .
Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome

Authors of this article:

Sabahat Ali1 Author Orcid Image ;   Sundas Khalid2 Author Orcid Image ;   Maham Afridi3 Author Orcid Image ;   Samar Akhtar4 Author Orcid Image ;   Yousef S Khader5 Author Orcid Image ;   Hashaam Akhtar4 Author Orcid Image
Article Authors Cited by (4) Tweetations (1) Metrics

Sabahat Ali   1 , MBBS, FCPS ;   Sundas Khalid   2 , MPhil ;   Maham Afridi   3 , MPhil ;   Samar Akhtar   4 , PhD ;   Yousef S Khader   5 , SCD ;   Hashaam Akhtar   4 , MPhil, PhD

1 Department Of Gynecology And Obstetrics, Pakistan Air Force Hospital, Islamabad, Pakistan

2 School of Chemical and Materials Engineering, National University of Science and Technology, Islamabad, Pakistan

3 Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan

4 Yusra Institute of Pharmaceutical Sciences, Islamabad, Pakistan

5 Department of Community Medicine, Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan

Corresponding Author:

  • Hashaam Akhtar, MPhil, PhD
  • Yusra Institute of Pharmaceutical Sciences
  • Zaraj Housing Society
  • Main GT Road
  • Islamabad, 44000
  • Pakistan
  • Phone: 92 3215272489
  • Email: hashaamakhtar@gmail.com